{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:03:18Z","timestamp":1789052598826,"version":"build-2803163510"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Mantle cell lymphoma (MCL) is a B cell malignancy that can be aggressive and with a poor prognosis; the clinical course is heterogeneous. The epidemiology of MCL in Asia is not well documented but appears to comprise 2\u20136% of all lymphoma cases based on available data, with variation observed between countries. Although international guidelines are available for the treatment of MCL, there is a lack of published data or guidance on the clinical characteristics and management of MCL in patient populations from Asia. This paper aims to review the available treatment and, where clinical gaps exist, provide expert consensus from the Asian Lymphoma Study Group (ALSG) on appropriate MCL management in Asia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Body<\/jats:title>\n                <jats:p>Management strategies for MCL are patient- and disease stage-specific and aim to achieve balance between efficacy outcomes and toxicity. For asymptomatic patients with clearly indolent disease, observation may be an appropriate strategy. For stage I\/II disease, following international guidelines is appropriate, which include either a short course of conventional chemotherapy followed by consolidated radiotherapy, less aggressive chemotherapy regimens, or a combination of these approaches. For advanced disease, the approach is based on the age and fitness of the patient. For young, fit patients, the current practice for induction therapy differs across Asia, with cytarabine having an important role in this setting. Hematopoietic stem cell transplantation (HSCT) may be justified in selected patients because of the high relapse risk. In elderly patients, specific chemoimmunotherapy regimens available in each country\/region are a treatment option. For maintenance therapy after first-line treatment, the choice of approach should be individualized, with cost being an important consideration within Asia. For relapsed\/refractory disease, ibrutinib should be considered as well as other follow-on compounds, if available.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Asian patient-specific data for the treatment of MCL are lacking, and the availability of treatment options differs between country\/region within Asia. Therefore, there is no clear one-size-fits-all approach and further investigation on the most appropriate sequence of treatment that should be considered for this heterogeneous disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13045-020-00855-9","type":"journal-article","created":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T15:02:39Z","timestamp":1584457359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group"],"prefix":"10.1186","volume":"13","author":[{"given":"Dok Hyun","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junning","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsai-Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yok Lam","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lim Soon","family":"Thye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deok Hwan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,17]]},"reference":[{"issue":"8","key":"855_CR1","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/ajh.24797","volume":"92","author":"JM Vose","year":"2017","unstructured":"Vose JM. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. American Journal of Hematology. 2017;92(8):806\u201313.","journal-title":"American Journal of Hematology."},{"issue":"16","key":"855_CR2","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","volume":"132","author":"K Maddocks","year":"2018","unstructured":"Maddocks K. Update on mantle cell lymphoma. Blood. 2018;132(16):1647\u201356.","journal-title":"Blood."},{"issue":"10","key":"855_CR3","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1053\/S0046-8177(03)00410-6","volume":"34","author":"L Nodit","year":"2003","unstructured":"Nodit L, Bahler DW, Jacobs SA, Locker J, Swerdlow SH. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Human Pathology. 2003;34(10):1030\u20134.","journal-title":"Human Pathology."},{"issue":"12","key":"855_CR4","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","volume":"101","author":"J Orchard","year":"2003","unstructured":"Orchard J, Garand R, Davis Z, Babbage G, Sahota S, Matutes E, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood. 2003;101(12):4975\u201381.","journal-title":"Blood."},{"issue":"32","key":"855_CR5","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1200\/JCO.2009.23.9731","volume":"27","author":"HE Eve","year":"2009","unstructured":"Eve HE, Furtado MV, Hamon MD, Rule SAJ. Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. J Clin Oncol. 2009;27(32):e189\u2013e90.","journal-title":"J Clin Oncol"},{"issue":"8","key":"855_CR6","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","volume":"27","author":"P Martin","year":"2009","unstructured":"Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27(8):1209\u201313.","journal-title":"J Clin Oncol"},{"issue":"1","key":"855_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/bjh.15283","volume":"182","author":"P McKay","year":"2018","unstructured":"McKay P, Leach M, Jackson B, Robinson S, Rule S. Guideline for the management of mantle cell lymphoma. Br J Haematol. 2018;182(1):46\u201362.","journal-title":"Br J Haematol"},{"issue":"11","key":"855_CR8","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","volume":"34","author":"CY Cheah","year":"2016","unstructured":"Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. Journal of Clinical Oncology. 2016;34(11):1256\u201369.","journal-title":"Journal of Clinical Oncology."},{"issue":"20","key":"855_CR9","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood."},{"key":"855_CR10","unstructured":"National Comprehensive Cancer Network. B-cell lymphomas. NCCN Guidelines Version 4.2019. 2019."},{"issue":"suppl_4","key":"855_CR11","doi-asserted-by":"publisher","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv62\u201371.","journal-title":"Ann Oncol"},{"issue":"1","key":"855_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/hon.2461","volume":"36","author":"Y Miao","year":"2017","unstructured":"Miao Y, Cao L, Sun Q, Li X-T, Wang Y, Qiao C, et al. Spectrum and immunophenotyping of 653 patients with B-cell chronic lymphoproliferative disorders in China: a single-centre analysis. Hematol Oncol. 2017;36(1):121\u20137.","journal-title":"Hematol Oncol"},{"key":"855_CR13","unstructured":"Prevalence of lymphoma subtypes in Shanxi according to latest WHO classification. Chin J Pathol. 2006;35(4):218-23."},{"issue":"35","key":"855_CR14","first-page":"e12120","volume":"97","author":"J Meng","year":"2018","unstructured":"Meng J, Chang C, Pan H, Zhu F, Xiao Y, Liu T, et al. Epidemiologic characteristics of malignant lymphoma in Hubei. China. Medicine. 2018;97(35):e12120.","journal-title":"China. Medicine."},{"issue":"4","key":"855_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/01.pai.0000176161.38402.b2","volume":"13","author":"J Wang","year":"2005","unstructured":"Wang J, Young L, Win W, Taylor CR. Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique. Appl Immunohistochem Mol Morphol. 2005;13(4):323\u201332.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"4","key":"855_CR16","first-page":"1036","volume":"25","author":"Y Wu","year":"2017","unstructured":"Wu Y, Wang H, Liu X-J, Wang Y-Y, Zhao W-L, Li J-M, et al. Clinical characteristics and outcome of 66 cases of mantle cell lymphomas. Zhongguo shi yan xue ye xue za zhi. 2017;25(4):1036\u201341.","journal-title":"Zhongguo shi yan xue ye xue za zhi."},{"issue":"4","key":"855_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/(SICI)1096-8652(199812)59:4<295::AID-AJH5>3.0.CO;2-N","volume":"59","author":"CS Chim","year":"1998","unstructured":"Chim CS, Chan ACL, Choo CK, Kwong YL, Lie AKW, Liang R. Mantle cell lymphoma in the Chinese: clinicopathological features and treatment outcome. Am J Hematol. 1998;59(4):295\u2013301.","journal-title":"Am J Hematol"},{"issue":"7","key":"855_CR18","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1023\/A:1008265532487","volume":"9","author":"JR Anderson","year":"1998","unstructured":"Anderson JR, Armitage JO, Weisenburger DD. For the Non-Hodgkin\u2019s Lymphoma Classification P. Epidemiology of the non-Hodgkin\u2019s lymphomas: distributions of the major subtypes differ by geographic locations. Ann Oncol. 1998;9(7):717\u201320.","journal-title":"Ann Oncol"},{"issue":"8","key":"855_CR19","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/ajh.20649","volume":"81","author":"M-Y Lee","year":"2006","unstructured":"Lee M-Y, Tan T-D, Feng A-C, Liu M-C. Clinicopathological analysis of 598 malignant lymphomas in Taiwan: seven-year experience in a single institution. Am J Hematol. 2006;81(8):568\u201375.","journal-title":"Am J Hematol"},{"issue":"3","key":"855_CR20","doi-asserted-by":"publisher","first-page":"254","DOI":"10.4132\/KoreanJPathol.2011.45.3.254","volume":"45","author":"J-M Kim","year":"2011","unstructured":"Kim J-M, Ko Y-H, Lee S-S, Huh J, Kang CS, Kim CW, et al. WHO classification of malignant lymphomas in Korea: report of the third nationwide study. Kor J Pathol. 2011;45(3):254.","journal-title":"Kor J Pathol"},{"issue":"1","key":"855_CR21","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4143\/crt.2017.093","volume":"50","author":"H Lee","year":"2018","unstructured":"Lee H, Park HJ, Park E-H, Ju HY, Oh C-M, Kong H-J, et al. Nationwide statistical analysis of lymphoid malignancies in Korea. Cancer Res Treat. 2018;50(1):222\u201338.","journal-title":"Cancer Res Treat"},{"issue":"4","key":"855_CR22","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s12185-018-2430-6","volume":"107","author":"H Miyoshi","year":"2018","unstructured":"Miyoshi H, Ohshima K. Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia\/lymphoma in Japan. Int J Hematol. 2018;107(4):420\u20137.","journal-title":"Int J Hematol"},{"issue":"1","key":"855_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0304-3835(98)00278-X","volume":"135","author":"K Ohshima","year":"1998","unstructured":"Ohshima K. B-Cell lymphoma of 708 cases in Japan: incidence rates and clinical prognosis according to the REAL classification. Cancer Letters. 1998;135(1):73\u201381.","journal-title":"Cancer Letters."},{"issue":"11","key":"855_CR24","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1002\/ijc.29635","volume":"137","author":"RBT Lim","year":"2015","unstructured":"Lim RBT, Loy EY, Lim GH, Zheng H, Chow KY, Lim ST. Gender and ethnic differences in incidence and survival of lymphoid neoplasm subtypes in an Asian population: secular trends of a population-based cancer registry from 1998 to 2012. Int J Cancer. 2015;137(11):2674\u201387.","journal-title":"Int J Cancer."},{"issue":"7","key":"855_CR25","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/jcp.2005.035071","volume":"59","author":"SS Chuang","year":"2006","unstructured":"Chuang SS. Striking male predominance of mantle cell lymphoma in Taiwan. J Clin Pathol. 2006;59(7):780.","journal-title":"J Clin Pathol"},{"issue":"8","key":"855_CR26","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/j.1440-1827.2006.01986.x","volume":"56","author":"S-S Chuang","year":"2006","unstructured":"Chuang S-S, Huang W-T, Hsieh P-P, Tseng H-H, Campo E, Colomer D, et al. Mantle cell lymphoma in Taiwan: clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2. Pathol Int. 2006;56(8):440\u20138.","journal-title":"Pathol Int"},{"issue":"1","key":"855_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.5045\/br.2014.49.1.15","volume":"49","author":"BW Kang","year":"2014","unstructured":"Kang BW, Sohn SK, Moon JH, Chae YS, Kim JG, Lee SJ, et al. Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: study by the consortium for improving survival of lymphoma. Blood Res. 2014;49(1):15.","journal-title":"Blood Res"},{"issue":"12","key":"855_CR28","doi-asserted-by":"publisher","first-page":"e508","DOI":"10.1016\/S1470-2045(13)70452-2","volume":"14","author":"AE Yeoh","year":"2013","unstructured":"Yeoh AE, Tan D, Li CK, Hori H, Tse E, Pui CH, et al. Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. Lancet Oncol. 2013;14(12):e508\u201323.","journal-title":"Lancet Oncol."},{"issue":"12","key":"855_CR29","doi-asserted-by":"publisher","first-page":"e548","DOI":"10.1016\/S1470-2045(13)70450-9","volume":"14","author":"D Tan","year":"2013","unstructured":"Tan D, Tan SY, Lim ST, Kim SJ, Kim WS, Advani R, et al. Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14(12):e548\u201361.","journal-title":"Lancet Oncol."},{"issue":"8","key":"855_CR30","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","volume":"124","author":"A Abrahamsson","year":"2014","unstructured":"Abrahamsson A, Albertsson-Lindblad A, Brown PN, Baumgartner-Wennerholm S, Pedersen LM, D\u2019Amore F, et al. Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. Blood. 2014;124(8):1288\u201395.","journal-title":"Blood."},{"key":"855_CR31","doi-asserted-by":"crossref","unstructured":"Jo JC, Kim SJ, Lee HS, Eom HS, Lee SI, Park Y, et al. Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: consortium for improving survival of lymphoma report. Ann Hematol. 2019.","DOI":"10.1007\/s00277-019-03803-x"},{"issue":"9","key":"855_CR32","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1093\/annonc\/mdx334","volume":"28","author":"BS Dabaja","year":"2017","unstructured":"Dabaja BS, Zelenetz AD, Ng AK, Tsang RW, Qi S, Allen PK, et al. Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG). Ann Oncol. 2017;28(9):2185\u201390.","journal-title":"Ann Oncol."},{"issue":"7","key":"855_CR33","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105(7):2677\u201384.","journal-title":"Blood."},{"issue":"13","key":"855_CR34","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","volume":"377","author":"S Le Gouill","year":"2017","unstructured":"Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377(13):1250\u201360.","journal-title":"N Engl J Med"},{"issue":"12","key":"855_CR35","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","volume":"16","author":"IF Khouri","year":"1998","unstructured":"Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, et al. Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998;16(12):3803\u20139.","journal-title":"J Clin Oncol"},{"issue":"7","key":"855_CR36","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","volume":"112","author":"CH Geisler","year":"2008","unstructured":"Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo\u2013purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112(7):2687\u201393.","journal-title":"Blood."},{"issue":"1","key":"855_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","volume":"121","author":"R Delarue","year":"2013","unstructured":"Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood. 2013;121(1):48\u201353.","journal-title":"Blood."},{"issue":"10044","key":"855_CR38","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65\u2009years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. The Lancet. 2016;388(10044):565\u201375.","journal-title":"The Lancet."},{"issue":"1","key":"855_CR39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/bjh.13929","volume":"173","author":"P Armand","year":"2016","unstructured":"Armand P, Redd R, Bsat J, Mayuram S, Giardino A, Fisher DC, et al. A phase 2 study of rituximab-bendamustine and rituximab-cytarabine for transplant-eligible patients with mantle cell lymphoma. Br J Haematol. 2016;173(1):89\u201395.","journal-title":"Br J Haematol"},{"issue":"5","key":"855_CR40","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/bjh.14480","volume":"176","author":"RW Chen","year":"2017","unstructured":"Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, et al. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol. 2017;176(5):759\u201369.","journal-title":"Br J Haematol."},{"issue":"5","key":"855_CR41","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S1473-3099(16)00118-3","volume":"16","author":"V Mallet","year":"2016","unstructured":"Mallet V, van B\u00f6mmel F, Doerig C, Pischke S, Hermine O, Locasciulli A, et al. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European conference on infections in leukaemia (ECIL-5). Lancet Infect Dis. 2016;16(5):606\u201317.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"855_CR42","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1007\/s12185-011-0845-4","volume":"93","author":"K Miura","year":"2011","unstructured":"Miura K, Takasaki H, Tsujimura H, Kanno M, Maeda Y, Tomita N, et al. Does more intensive therapy have effects on mantle cell lymphoma? A clinical experience from the Lymphoma Treatment Study Group in Japan. Int J Hematol. 2011;93(5):684\u20136.","journal-title":"Int J Hematol"},{"issue":"9","key":"855_CR43","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/jnci\/djk152","volume":"99","author":"H Schulz","year":"2007","unstructured":"Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, et al. Immunochemotherapy With rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99(9):706\u201314.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"855_CR44","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"G Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E, W\u00f6rmann B, D\u00fchrsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23(9):1984\u201392.","journal-title":"J Clin Oncol"},{"issue":"6","key":"855_CR45","first-page":"520","volume":"367","author":"HC Kluin-Nelemans","year":"2012","unstructured":"Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, et al. Treatment of older patients with mantle-cell lymphoma. J Clin Oncol. 2012;367(6):520\u201331.","journal-title":"J Clin Oncol"},{"issue":"9873","key":"855_CR46","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. The Lancet. 2013;381(9873):1203\u201310.","journal-title":"The Lancet."},{"issue":"10","key":"855_CR47","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa1412096","volume":"372","author":"T Robak","year":"2015","unstructured":"Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372(10):944\u201353.","journal-title":"N Engl J Med"},{"issue":"19","key":"855_CR48","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","volume":"373","author":"J Ruan","year":"2015","unstructured":"Ruan J, Martin P, Shah B, Schuster SJ, Smith SM, Furman RR, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Eng J Med. 2015;373(19):1835\u201344.","journal-title":"N Eng J Med"},{"issue":"4","key":"855_CR49","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","volume":"23","author":"M Ghielmini","year":"2005","unstructured":"Ghielmini M, Schmitz S-FH, Cogliatti S, Bertoni F, Waltzer U, Fey MF, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2005;23(4):705\u201311.","journal-title":"J Clin Oncol"},{"key":"855_CR50","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.2147\/OTT.S150339","volume":"11","author":"J Jin","year":"2018","unstructured":"Jin J, Okamoto R, Yoon S-S, Shih L-Y, Zhu J, Liu T, et al. Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma. Onco Targets Ther. 2018;11:3869\u201382.","journal-title":"Onco Targets Ther"},{"issue":"4","key":"855_CR51","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s12185-016-2146-4","volume":"105","author":"M Ogura","year":"2016","unstructured":"Ogura M, Ishizawa K, Maruyama D, Uike N, Ando K, Izutsu K, et al. Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan. Int J Hematol. 2016;105(4):470\u20137.","journal-title":"Int J Hematol"},{"issue":"4","key":"855_CR52","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/ccr3.195","volume":"3","author":"TM Abkur","year":"2015","unstructured":"Abkur TM, Saeed M, Ahmed SZ, McArthur R, Leahy M, O\u2019Leary H, et al. Pneumocystis jiroveci prophylaxis in patients undergoing bendamustine treatment: the need for a standardized protocol. Clin Case Reports. 2015;3(4):255\u20139.","journal-title":"Clin Case Reports."},{"issue":"22","key":"855_CR53","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1200\/JCO.2010.33.7055","volume":"29","author":"LE Budde","year":"2011","unstructured":"Budde LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM, et al. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol. 2011;29(22):3023\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"855_CR54","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","volume":"158","author":"CH Geisler","year":"2012","unstructured":"Geisler CH, Kolstad A, Laurell A, Jerkeman M, R\u00e4ty R, Andersen NS, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012;158(3):355\u201362.","journal-title":"Br J Haematol"},{"issue":"9","key":"855_CR55","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s00277-014-2087-z","volume":"93","author":"WH Kr\u00fcger","year":"2014","unstructured":"Kr\u00fcger WH, Hirt C, Basara N, Sayer HG, Behre G, Fischer T, et al. Allogeneic stem cell transplantation for mantle cell lymphoma\u2014final report from the prospective trials of the East German Study Group Haematology\/Oncology (OSHO). Ann Hematol. 2014;93(9):1587\u201397.","journal-title":"Ann Hematol"},{"issue":"4","key":"855_CR56","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2013.01.009","volume":"19","author":"M Hamadani","year":"2013","unstructured":"Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2013;19(4):625\u201331.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"855_CR57","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1182\/blood.V120.21.474.474","volume":"120","author":"S Dietrich","year":"2012","unstructured":"Dietrich S, Finel H, Boumendil A, Avivi I, Volin L, Cornelissen J, et al. Outcome and prognostic factors in patients with mantle cell lymphoma relapsing after autologous stem cell transplantation: a retrospective study of the EBMT. Blood. 2012;120(21):474.","journal-title":"Blood"},{"issue":"21","key":"855_CR58","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.1182\/blood.V124.21.3985.3985","volume":"124","author":"SA Graf","year":"2014","unstructured":"Graf SA, Stevenson PA, Holmberg LA, Till BG, Press OW, Chauncey TR, et al. Rituximab maintenance therapy after autologous stem cell transplantation improves survival of patients with mantle cell lymphoma. Blood. 2014;124(21):3985.","journal-title":"Blood"},{"issue":"3","key":"855_CR59","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/leu.2013.332","volume":"28","author":"S Dietrich","year":"2013","unstructured":"Dietrich S, Weidle J, Rieger M, Meissner J, Radujkovic A, Ho AD, et al. Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma. Leukemia. 2013;28(3):708\u20139.","journal-title":"Leukemia."},{"issue":"25","key":"855_CR60","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2012.42.2444","volume":"30","author":"MR Smith","year":"2012","unstructured":"Smith MR, Li H, Gordon L, Gascoyne RD, Paietta E, Forero-Torres A, et al. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90\u2013ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol. 2012;30(25):3119\u201326.","journal-title":"J Clin Oncol"},{"issue":"4","key":"855_CR61","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1097\/HS9.0000000000000136","volume":"2","author":"L Vidal","year":"2018","unstructured":"Vidal L, Gafter-Gvili A, Dreyling M, Ghielmini M, Witzens-Harig M, Shpilberg O, et al. Maintenance treatment for patients with mantle cell lymphoma. HemaSphere. 2018;2(4):e136.","journal-title":"HemaSphere."},{"issue":"1","key":"855_CR62","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","volume":"17","author":"ML Wang","year":"2016","unstructured":"Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. The Lancet Oncology. 2016;17(1):48\u201356.","journal-title":"The Lancet Oncology."},{"issue":"10020","key":"855_CR63","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","volume":"387","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. The Lancet. 2016;387(10020):770\u20138.","journal-title":"The Lancet."},{"issue":"6","key":"855_CR64","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507\u201316.","journal-title":"N Engl J Med"},{"issue":"11","key":"855_CR65","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1093\/annonc\/mdt366","volume":"24","author":"PL Zinzani","year":"2013","unstructured":"Zinzani PL, Vose JM, Czuczman MS, Reeder CB, Haioun C, Polikoff J, et al. Long-term follow-up of lenalidomide in relapsed\/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol. 2013;24(11):2892\u20137.","journal-title":"Ann Oncol"},{"issue":"29","key":"855_CR66","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","volume":"31","author":"A Goy","year":"2013","unstructured":"Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31(29):3688\u201395.","journal-title":"J Clin Oncol"},{"issue":"3","key":"855_CR67","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","volume":"17","author":"M Trn\u011bn\u00fd","year":"2016","unstructured":"Trn\u011bn\u00fd M, Lamy T, Walewski J, Belada D, Mayer J, Radford J, et al. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. The Lancet Oncol. 2016;17(3):319\u201331.","journal-title":"The Lancet Oncol"},{"issue":"8","key":"855_CR68","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/s41375-018-0023-2","volume":"32","author":"S Rule","year":"2018","unstructured":"Rule S, Jurczak W, Jerkeman M, Rusconi C, Trneny M, Offner F, et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia. 2018;32(8):1799\u2013803.","journal-title":"Leukemia."},{"issue":"5","key":"855_CR69","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","volume":"104","author":"S Rule","year":"2018","unstructured":"Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, et al. Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica. 2018;104(5):e211\u2013e4.","journal-title":"Haematologica."},{"issue":"30","key":"855_CR70","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24(30):4867\u201374.","journal-title":"J Clin Oncol"},{"issue":"4","key":"855_CR71","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1365-2141.2010.08340.x","volume":"151","author":"A Agathocleous","year":"2010","unstructured":"Agathocleous A, Rohatiner A, Rule S, Hunter H, Kerr JP, Neeson SM, et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstr\u00f6m macroglobulinaemia. Br J Haematol. 2010;151(4):346\u201353.","journal-title":"Br J Haematol"},{"issue":"7","key":"855_CR72","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","volume":"13","author":"M Wang","year":"2012","unstructured":"Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial. The Lancet Oncol. 2012;13(7):716\u201323.","journal-title":"The Lancet Oncol"},{"issue":"10121","key":"855_CR73","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. The Lancet. 2018;391(10121):659\u201367.","journal-title":"The Lancet."},{"key":"855_CR74","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/hon.55_2630","volume":"37","author":"CS Tam","year":"2019","unstructured":"Tam CS, Wang M, Simpson D, Opat S, Cull G, Munoz J, et al. Updated Safety and efficacy data in in the phase 1 trial of patients with mantle cell lymphoma (MCL) treated with Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111). Hematol Oncol. 2019;37:245\u20137.","journal-title":"Hematol Oncol"},{"issue":"5","key":"855_CR75","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/BF02982806","volume":"76","author":"K Tobinai","year":"2002","unstructured":"Tobinai K. Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan. International Journal of Hematology. 2002;76(5):411\u20139.","journal-title":"International Journal of Hematology."},{"issue":"6","key":"855_CR76","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/annonc\/mdf155","volume":"13","author":"T Igarashi","year":"2002","unstructured":"Igarashi T, Kobayashi Y, Ogura M, Kinoshita T, Ohtsu T, Sasaki Y, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol. 2002;13(6):928\u201343.","journal-title":"Ann Oncol"},{"issue":"3","key":"855_CR77","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s12185-018-02577-8","volume":"109","author":"K Tobinai","year":"2019","unstructured":"Tobinai K, Uchida T, Fukuhara N, Nishikawa T. Ibrutinib in Japanese patients with relapsed\/refractory B-cell malignancies: final analysis of phase I study. Int J Hematol. 2019;109(3):366\u20138.","journal-title":"Int J Hematol"},{"issue":"2","key":"855_CR78","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3960\/jslrt.19006","volume":"59","author":"D Maruyama","year":"2019","unstructured":"Maruyama D, Nagai H, Fukuhara N, Kitano T, Ishikawa T, Nishikawa T. Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed\/refractory mantle cell lymphoma. J Clin Exp Hematop. 2019;59(2):98\u2013100.","journal-title":"J Clin Exp Hematop"},{"issue":"16","key":"855_CR79","doi-asserted-by":"publisher","first-page":"6860","DOI":"10.1002\/cam4.2565","volume":"8","author":"YW Jeon","year":"2019","unstructured":"Jeon YW, Yoon S, Min GJ, Park SS, Park S, Yoon JH, et al. Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience. Cancer Medicine. 2019;8(16):6860\u201370.","journal-title":"Cancer Medicine."},{"key":"855_CR80","doi-asserted-by":"crossref","unstructured":"Yi JH, Kim WS, Kim SJ, Yoon DH, Suh C, Chang MH, et al. LBA13Clinical outcomes of ibrutinib in patients with relapsed or refractory mantle cell lymphoma: Korean multicenter, retrospective analysis. Ann Oncol. 2019;30(Supplement_9).","DOI":"10.1093\/annonc\/mdz446.012"},{"key":"855_CR81","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1200\/EDBK_100021","volume":"39","author":"B Nazha","year":"2019","unstructured":"Nazha B, Mishra M, Pentz R, Owonikoko TK. Enrollment of racial minorities in clinical trials: old problem assumes new urgency in the age of immunotherapy. Am Soc Clin Oncol Educ Book. 2019;39:3\u201310.","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00855-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-020-00855-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00855-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:33:26Z","timestamp":1615941206000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-020-00855-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,17]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["855"],"URL":"https:\/\/doi.org\/10.1186\/s13045-020-00855-9","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,17]]},"assertion":[{"value":"4 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Won Seog Kim reports research funding from Johnson & Johnson, Kyowa-Kirin, Pfizer, Roche, Donga, and Celltrion. Koji Izutsu reports the following disclosures related to the treatment of MCL: grants and personal fees from Celgene, grants and personal fees from Eisai, grants and personal fees from Janssen, grants and personal fees from Mundipharma, grants and personal fees from Chugai, grants and personal fees from AstraZeneca, grants and personal fees from Abbvie, grants and personal fees from Zenyaku, grants from Symbio, and personal fees from Kyowa Hakko Kirin outside the submitted work. Dok-Hyun Yoon reports research funding from Johnson & Johnson and consulting fees from Johnson & Johnson, Celgene, and Celltrion. Junning Cao, Tsai-Yun Chen, Seok Jin Kim, Yok Lam Kwong, Tony Yu Lin, Lim Soon Thye, Bing Xu, and Duk Hwan Yong report no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}